Home PipelineMGD007 (gpA33 x CD3)

Background

MGD007 is a humanized DART® molecule that recognizes both the glycoprotein A33 antigen, or gpA33, and CD3. The gpA33 antigen is expressed on gastrointestinal tumors, including more than 95% of human colon cancers. MGD007 was designed to redirect T cells, via their CD3 component, to kill gpA33-expressing cells.

Clinical Development

MGD007 is being tested in patients with colorectal cancer in a Phase 1 clinical study in combination with MGA012.

Our Rights

MacroGenics retains full worldwide rights to MGD007.

Clinical Trials

Presentations

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close